Diagnostics
PreciseDx Secures $20.7 Million in Series B Funding to Enhance AI-Driven Breast Cancer Risk Assessments
PreciseDx, AI-Powered Cancer Risk Assessments, Breast Cancer Diagnostics, Series B Funding, Precision Medicine
Illumina’s Board Approves Spin-Off of Grail, a Cancer Diagnostics Firm
Illumina, Grail, spin-off, cancer diagnostics, DNA sequencing
Life Sciences Senior Associate: Evaluating Opportunities in Therapeutics, Diagnostics, and Health Tech
Life Sciences Senior Associate, Therapeutics, Diagnostics, Research Tools, Health Technology, Opportunity Evaluation, Diligence